



# **R** **RESEARCH OPPORTUNITIES** **ALERT**

Issue 37: Volume 1b



## **GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)** (Quarter: July – August, 2019)

*A Compilation by the*

PRE- & POST AWARD SERVICES  
OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID)  
UNIVERSITY OF GHANA

**JUNE 2019**

**Research Grants**

**Innovation Grants**

**Academic-Industry Grants**

**Collaborative Opportunities**

**Technology Development Grants**



## TABLE OF CONTENT

Research projects in cancer systems biology (U01 clinical trial optional) .....	5
BRAIN initiative – targeted BRAIN circuits planning projects (R34 clinical trial not allowed) .....	5
Research funding .....	5
Provocative questions in multiple myeloma disparities research (R01 clinical trial optional).....	5
Provocative questions in multiple myeloma disparities research (R21 clinical trial optional).....	6
Research to improve adolescent health in low- and middle-income countries .....	6
Annual funding call .....	6
Investigator-initiated research in computational genomics and data science (R01 clinical trial not allowed) .....	6
Investigator-initiated research in computational genomics and data science (R21 clinical trial not allowed) .....	7
Exploiting omics assays to investigate molecular regulation of persistent HIV in individuals with substance use disorder (R61/R33 clinical trial optional) .....	7
Exploring epigenomic or non-coding RNA regulation in the development, maintenance, or treatment of chronic pain (R61/R33 clinical trial optional) .....	7
CREATE bio optimisation track for biologics (U01) .....	8
CREATE bio development track – nonclinical and early-phase clinical development for biologics (U01 clinical trial optional) .....	8
Analytical validation of candidate biomarkers for neurological disease (U01 clinical trial optional) .....	8
Clinical validation of a candidate biomarker for neurological disease (U01 clinical trial optional).....	8
Tobacco regulatory science (R01 clinical trial optional).....	9
Research education programme for clinical researchers and clinicians (R25 clinical trial optional) .....	9
Feasibility of novel diagnostics for tuberculosis in endemic countries (U01 clinical trial not allowed) .....	9
Behavioural and integrative treatment development programme (R01 clinical trial optional).....	9
Behavioural and integrative treatment development programme (R34 clinical trial optional).....	10
Programme grants for applied research, competition 30.....	10



Research for patient benefit programme, round 39 – including frailty and chronic pain themed calls .....	10
Device-based treatments for substance use disorders (UG3/UH3 clinical trial optional) .....	10
Global infectious disease research training programme (D43 clinical trial optional) .....	11
Strategic alliances for medications development to treat substance use disorders (R01 clinical trial optional) .....	11
.....	11
Grand opportunity in medications development for substance-use disorders (U01 clinical trial optional) .....	11
NIDA translational avant-garde award for development of medication to treat substance use disorders (UG3/UH3 clinical trial optional) .....	12
Oral health in people living with HIV and additional non-communicable diseases (R01 clinical trial not allowed) .....	12
Physical sciences-oncology network – physical sciences-oncology projects (U01 clinical trial optional) .....	12
Advancing biomarker discovery and novel point-of-care diagnostics for active TB disease detection in HIV-1 infected and exposed children (R01 clinical trial optional) .....	13
Global infectious disease research administration development award for low- and middle-income country institutions (G11 clinical trial not allowed) .....	13
Drug screening with biofabricated 3D skin disease tissue models (U18 clinical trial not allowed) .....	13
Global health policy and systems research programme – development awards .....	14
.....	14
Innovation for HIV vaccine discovery (R01) .....	14
Provocative questions in cancer with an underlying HIV infection (R01 clinical trial optional) .....	14
Targeted prevention for tick-borne diseases (R01 clinical trial not allowed) .....	15
Translational research in paediatric and obstetric pharmacology and therapeutics (R21 clinical trial optional) .....	15
Translational research in pediatric and obstetric pharmacology and therapeutics (R03) .....	15
Translational research in pediatric and obstetric pharmacology and therapeutics (R01 clinical trial optional) .....	16
Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional) .....	16
Utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01 clinical trial not allowed) .....	16



Clinical trial readiness for rare neurological and neuromuscular diseases (U01 clinical trial not allowed) .....	17
NIDA avant-garde award programme for HIV/AIDS and drug use research (DP1 clinical trial optional) .....	17
Inter-organelle communication in cancer (R21) .....	17
Inter-organelle communication in cancer (R01) .....	17
Efficacy and mechanism evaluation programme – commissioned call: 19/21 .....	18
Limited competition cohort studies of HIV/AIDS and substance abuse (U01 clinical trial not allowed) .....	18
Cutting-edge basic research awards (R21 clinical trial optional) .....	18
Planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71) .....	19
Fogarty HIV research training programme for low- and middle-income country institutions (D43 clinical trial optional) .....	19
Infrastructure development training programmes for critical HIV research at low- and middle-income country institutions (G11 clinical trials not allowed) ..	19
Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviours (U01 clinical trial not allowed) .....	19
International research in infectious diseases (R01): AIDS-related .....	20
Advancing exceptional research on HIV/AIDS and substance abuse (R01 clinical trial optional) .....	20
Efficacy and mechanism evaluation programme – researcher-led workstream: 19/24 .....	20
Efficacy and mechanism evaluation programme – primary research topic: 19/22 .....	21



# JULY

## Research projects in cancer systems biology (U01 clinical trial optional)

### **NIH: National Cancer Institute**

This supports collaborative research projects that use systems biology approaches to address challenges relating to cancer initiation, progression and treatment. Funding

is worth up to USD 400,000 per year over a maximum period of five years.

**Closing date: 15 Jul 19**

[Link to \\*Research Professional](#)

## BRAIN initiative – targeted BRAIN circuits planning projects (R34 clinical trial not allowed)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behaviour. The combined budget for

direct costs for the two year project may not exceed USD 450,000.

**Closing date: 15 Jul 19**

[Link to \\*Research Professional](#)

## Research funding

### **CARB-X**

This supports research into the development of antibiotics, vaccines, diagnostics, devices and other products to combat drug-resistant bacteria.

**Closing date: 15 Jul 19**

[Link to \\*Research Professional](#)

## Provocative questions in multiple myeloma disparities research (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This supports research projects designed to solve specific problems and paradoxes in multiple myeloma

and disparities research identified as the multiple myeloma disparities



provocative questions. The maximum project period is 5 years.

**Closing date: 15 Jul 19**

[Link to \\*Research Professional](#)



### Provocative questions in multiple myeloma disparities research (R21 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports research to solve specific problems and paradoxes in multiple myeloma and disparities research. Grants are worth up to USD 275,000 each for two years.

**Closing date: 15 Jul 19**

[Link to \\*Research Professional](#)



### Research to improve adolescent health in low- and middle-income countries

#### **Medical Research Council**

This builds and strengthens research partnerships and promote capacity building in global adolescent health research. The total budget is worth

up to £8 million over five years for eight to 12 projects.

**Closing date: 16 Jul 19**

[Link to \\*Research Professional](#)



### Annual funding call

#### **Enhancing Learning and Research for Humanitarian Assistance**

This supports research that will strengthen the evidence base around public health interventions, and thereby lead to more effective public health interventions in humanitarian

crises. The maximum grant period is four years.

**Closing date: 16 Jul 19**

[Link to \\*Research Professional](#)



### Investigator-initiated research in computational genomics and data science (R01 clinical trial not allowed)

#### **NIH: National Human Genome Research Institute**

This supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage

development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics



community. Funding is for up to five years.

**Closing date: 16 Jul 19**

[Link to \\*Research Professional](#)

### Investigator-initiated research in computational genomics and data science (R21 clinical trial not allowed)

#### **NIH: National Human Genome Research Institute**

This supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to

the biomedical genomics community. Direct costs are limited to USD 275,000 over a two-year project period.

**Closing date: 16 Jul 19**

[Link to \\*Research Professional](#)

### Exploiting omics assays to investigate molecular regulation of persistent HIV in individuals with substance use disorder (R61/R33 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports projects that exploit omics assays to address outstanding questions regarding molecular regulation of persistent HIV in the context of chronic substance use or substance use disorder. Budgets are limited to USD 450,000 per year for

up to three years in the R61 phase and USD 650,000 per year for up to two years in the R33 phase.

**Closing date: 17 Jul 19**

[Link to \\*Research Professional](#)

### Exploring epigenomic or non-coding RNA regulation in the development, maintenance, or treatment of chronic pain (R61/R33 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports the investigation of the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance or treatment of chronic pain. Grants are worth up to USD 300,000 per year for up to two years for the R61 phase and up to USD 450,000 per

year for up to three years for the R33 phase.

**Closing date: 17 Jul 19**

[Link to \\*Research Professional](#)




---

## CREATE bio optimisation track for biologics (U01)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. Budgets will normally remain under USD 500,000 in direct costs in any given

year. The project period cannot exceed five years.

**Closing date: 18 Jul 19**

[Link to \\*Research Professional](#)

---

## CREATE bio development track – nonclinical and early-phase clinical development for biologics (U01 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports the development of therapeutic biotechnology products and biologics for disorders that fall under the institute's mission. Applications should not exceed USD

2.5 million. The total project duration is five years.

**Closing date: 18 Jul 19**

[Link to \\*Research Professional](#)

---

## Analytical validation of candidate biomarkers for neurological disease (U01 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports analytical validation of candidate biomarker measures or endpoints. Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

**Closing date: 18 Jul 19**

[Link to \\*Research Professional](#)

---

## Clinical validation of a candidate biomarker for neurological disease (U01 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports rigorous clinical evaluation of a candidate biomarker using retrospective or prospective methods in a manner that is

consistent with the purpose of the biomarker. Funding is for five years.

**Closing date: 18 Jul 19**

[Link to \\*Research Professional](#)





## Tobacco regulatory science (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This supports biomedical and behavioural research that provides scientific data to inform regulation of tobacco products to protect public health. Application budgets are limited to USD 300,000 in direct

costs per year for a maximum project period of three years.

**Closing date: 19 Jul 19**

[Link to \\*Research Professional](#)

## Research education programme for clinical researchers and clinicians (R25 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports educational activities that complement and enhance the training of a workforce to meet the nation's biomedical, behavioural and clinical research needs. Grants are

worth up to USD 350,000 per year for up to five years.

**Closing date: 22 Jul 19**

[Link to \\*Research Professional](#)

## Feasibility of novel diagnostics for tuberculosis in endemic countries (U01 clinical trial not allowed)

### **NIH: National Institute of Allergy and Infectious Diseases**

This enables the evaluation of early stage diagnostics and novel diagnostic strategies for tuberculosis in the context of existing clinical algorithms in tuberculosis endemic countries. The total budget is USD 4

million in fiscal year 2020 to fund one to two awards.

**Closing date: 22 Jul 19**

[Link to \\*Research Professional](#)

## Behavioural and integrative treatment development programme (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports research on the development and testing of behavioural and integrative treatments for drug and alcohol use, abuse and dependence. The

maximum project period is five years.

**Closing date: 23 Jul 19**

[Link to \\*Research Professional](#)



## Behavioural and integrative treatment development programme (R34 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports research on the development and testing of behavioural and integrative treatments for drug and alcohol use, abuse and dependence. Application

budgets are limited to USD 450,000 over three years.

**Closing date: 23 Jul 19**

[Link to \\*Research Professional](#)



## Programme grants for applied research, competition 30

### **Department of Health and Social Care including NIHR**

This enables NHS and academic partners to work together, addressing complex healthcare problems, in ways not always possible through other programmes.

Awards are usually worth up to £2.5 million each over six years.

**Closing date: 24 Jul 19**

[Link to \\*Research Professional](#)



## Research for patient benefit programme, round 39 – including frailty and chronic pain themed calls

### **Department of Health and Social Care including NIHR**

This supports research concerned with the day-to-day practice of health service staff, and that has the potential to have an impact on the health or well-being of patients and users of the NHS. Grants for

individual projects are worth up to £350,000 each for up to three years.

**Closing date: 24 Jul 19**

[Link to \\*Research Professional](#)



## Device-based treatments for substance use disorders (UG3/UH3 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This aims to accelerate the development of devices to treat substance use disorders. Budgets are limited to USD 500,000 direct costs for the entire UG3 phase, but are not limited for the UH3 phase. The

project period is limited to two years for the UG3 phase and three years for the UH3 phase.

**Closing date: 24 Jul 19**

[Link to \\*Research Professional](#)




---

## Global infectious disease research training programme (D43 clinical trial optional)

### **NIH: Fogarty International Center**

This supports collaborative training programmes that will strengthen the capacity of a low- and middle income country institution to conduct infectious disease research.

Application budgets are limited to USD 230,000 per year for new

awards; USD 276,000 for renewal awards. The maximum project period is five years.

**Closing date: 25 Jul 19**

[Link to \\*Research Professional](#)

---

## Strategic alliances for medications development to treat substance use disorders (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports research that advances compounds towards Federal Drug Administration approval by leveraging National Institute on Drug Abuse funds with the strengths and resources of outside organisations, such as for-

profit and not-for-profit entities. Application budgets are worth up to USD 3 million per year for maximum period of three years.

**Closing date: 25 Jul 19**

[Link to \\*Research Professional](#)

---

## Grand opportunity in medications development for substance-use disorders (U01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This aims to accelerate the development of medication for the treatment of substance-use disorders by encouraging research applications to support a diverse array of preclinical and clinical research projects. Two to three awards per year, each worth up to

USD 5 million per year, are available. The maximum project period is three years.

**Closing date: 25 Jul 19**

[Link to \\*Research Professional](#)







## Global health policy and systems research programme – development awards

### **Department of Health and Social Care including NIHR**

These support underpinning work for the development of applications able to compete for research funding in global health policy and systems research. Awards are worth up to

£100,000 each over up to nine months.

**Closing date: 31 Jul 19**

[Link to \\*Research Professional](#)

## AUGUST

### Innovation for HIV vaccine discovery (R01)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports high risk, high impact early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV.

Application budgets are limited to a total of USD 350,000 in direct costs per year. An additional USD 150,000 may be requested in direct costs per

year when research in nonhuman primate or humanised mice models is proposed and justified.

**Closing date: 01 Aug 19**

[Link to \\*Research Professional](#)

### Provocative questions in cancer with an underlying HIV infection (R01 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports projects that contribute to the understanding of the risks, development, progression, diagnosis and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS by addressing one of the

institute's proposed provocative questions. The maximum project period is five years.

**Closing date: 01 Aug 19**

[Link to \\*Research Professional](#)



## Targeted prevention for tick-borne diseases (R01 clinical trial not allowed)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of vaccines and other approaches for the prevention of Lyme disease and other tick-borne diseases in humans using both established and novel

technologies. The maximum project period is five years.

**Closing date: 06 Aug 19**

[Link to \\*Research Professional](#)

## Translational research in paediatric and obstetric pharmacology and therapeutics (R21 clinical trial optional)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports translational and clinical research as well as clinical trials that will advance knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during

pregnancy and lactation. Direct costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 Aug 19**

[Link to \\*Research Professional](#)

## Translational research in pediatric and obstetric pharmacology and therapeutics (R03)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and

lactation. Application budgets are limited to USD 50,000 in direct costs per year. The maximum project period is two years.

**Closing date: 07 Aug 19**

[Link to \\*Research Professional](#)



## Translational research in pediatric and obstetric pharmacology and therapeutics (R01 clinical trial optional)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports translational and clinical research as well as clinical trials that will advance knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during

[Link to \\*Research Professional](#)

pregnancy and lactation. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 Aug 19**



## Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports neuroscience investigators seeking to advance their small molecule drug discovery and development projects into the clinic. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

**Closing date: 09 Aug 19**

[Link to \\*Research Professional](#)



## Utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01 clinical trial not allowed)

### **NIH: National Cancer Institute**

This supports research in cancer aetiology and early-detection biomarkers, using the biorepository resources of the National Cancer Institute-sponsored prostate, lung, colorectal and ovarian cancer

screening trial. Application budgets are not limited. The maximum project period is five years.

**Closing date: 14 Aug 19**

[Link to \\*Research Professional](#)







## Clinical trial readiness for rare neurological and neuromuscular diseases (U01 clinical trial not allowed)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. Grants

are worth up to USD 650,000 each per year over five years.

**Closing date: 14 Aug 19**

[Link to \\*Research Professional](#)



## NIDA avant-garde award programme for HIV/AIDS and drug use research (DP1 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports individual scientists who propose high impact research that will open new areas of HIV/AIDS research relevant to drug abuse or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. Application budgets are limited to

USD 500,000 in direct costs per year for a maximum project duration of five years.

**Closing date: 14 Aug 19**

[Link to \\*Research Professional](#)



## Inter-organelle communication in cancer (R21)

### **NIH: National Cancer Institute**

This supports research projects that examine how inter-organelle communication in cancer cells and tumour-associated cells affects cellular function, adaptation and phenotypic plasticity. Direct costs are limited to USD 275,000 over a

two-year project period, with no more than USD 200,000 in direct costs allowed in any single year.

**Closing date: 14 Aug 19**

[Link to \\*Research Professional](#)



## Inter-organelle communication in cancer (R01)

### **NIH: National Cancer Institute**



This supports research projects that examine how inter-organelle communication in cancer cells and tumour-associated cells affects cellular function, adaptation and phenotypic plasticity. Application budgets are not limited but need to

reflect the actual needs of the proposed project.

**Closing date: 14 Aug 19**

[Link to \\*Research Professional](#)

---

### Efficacy and mechanism evaluation programme – commissioned call: 19/21

#### **Department of Health and Social Care including NIHR**

This supports hypothesis driven research into the underlying mechanisms of action of clinical and public health interventions. There are no fixed limits on the duration of projects or the level of funding.

**Closing date: 15 Aug 19**

[Link to \\*Research Professional](#)

---

### Limited competition cohort studies of HIV/AIDS and substance abuse (U01 clinical trial not allowed)

#### **NIH: National Institute on Drug Abuse**

This supports the maintenance and expansion of existing National Institute on Drug Abuse-funded cohorts to continue addressing new emerging or high-priority research on multidisciplinary aspects of

HIV/AIDS and substance abuse. The maximum award period is five years.

**Closing date: 15 Aug 19**

[Link to \\*Research Professional](#)

---

### Cutting-edge basic research awards (R21 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This aims to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention or treatment of substance abuse disorders. Direct costs are limited to USD 275,000 over a two-year project

period, with no more than USD 150,000 in any single year.

**Closing date: 20 Aug 19**

[Link to \\*Research Professional](#)




---

**Planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71)**

**NIH: Fogarty International Center**

This supports research training that strengthens HIV research capacity of institutions in low- and middle-income countries. Application budgets are limited to USD 28,000

per year for a maximum of two years.

**Closing date: 20 Aug 19**

[Link to \\*Research Professional](#)

---

**Fogarty HIV research training programme for low- and middle-income country institutions (D43 clinical trial optional)**

**NIH: Fogarty International Center**

This aims to strengthen the scientific capacity of institutions in low- and middle-income countries to conduct HIV research relevant to the evolving HIV epidemic in their country. Application budgets are

limited to USD 280,000 per year for up to five years.

**Closing date: 20 Aug 19**

[Link to \\*Research Professional](#)

---

**Infrastructure development training programmes for critical HIV research at low- and middle-income country institutions (G11 clinical trials not allowed)**

**NIH: Fogarty International Center**

This aims to strengthen the scientific capacity of institutions in low- and middle-income countries to conduct HIV research on the evolving HIV epidemic in their countries. Application budgets are limited to

USD 92,000 per year for a maximum period of three years.

**Closing date: 20 Aug 19**

[Link to \\*Research Professional](#)

---

**Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviours (U01 clinical trial not allowed)**

**NIH: National Institute on Drug Abuse**

This supports the discovery of allelic variants, genomic alterations and

functional changes associated with addictive behaviours in non-human



animals through systems studies that employ genetic and genomics strategies. Funding is for up to five years.

**Closing date: 21 Aug 19**

[Link to \\*Research Professional](#)

---

## International research in infectious diseases (R01): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related announcement encourages applications, from organisations or institutions in eligible foreign countries, that propose research related to infectious diseases that are of interest or importance to that country with the intent of local

scientific expertise. Applications may request a budget of up to USD 125,000 per year in direct costs for a maximum period of a five years.

**Closing date: 22 Aug 19**

[Link to \\*Research Professional](#)

---

## Advancing exceptional research on HIV/AIDS and substance abuse (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports innovative research projects that have the potential to open new areas of HIV/AIDS research or lead to new avenues for prevention and treatment of

HIV/AIDS among substance abusers. Funding is for five years.

**Closing date: 22 Aug 19**

[Link to \\*Research Professional](#)

---

## Efficacy and mechanism evaluation programme – researcher-led workstream: 19/24

### **Department of Health and Social Care including NIHR**

\*\*\* The closing date for this opportunity has been extended. The previous deadline of 15 August has been extended to 28 August 2019. All other call details remain unchanged. This call supports studies evaluating interventions that

make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. There are no fixed limits on the duration of projects or funding. \*\*\*



**Closing date: 28 Aug 19**

[Link to \\*Research Professional](#)



**Efficacy and mechanism evaluation programme – primary research topic: 19/22**

**Department of Health and Social Care including NIHR**

This call supports research on tobacco cessation, control and harm reduction interventions. There are no fixed limits on the duration of projects or the level of funding. \*\*\*

**Closing date: 28 Aug 19**

[Link to \\*Research Professional](#)

